Latest news with #LLR
Time of India
06-08-2025
- Time of India
Official reprimanded for slow pace of LLR hosp work
Kanpur: District magistrate Jitendra Pratap Singh conducted a surprise inspection of the ongoing projects at Lala Lajpat Rai (LLR) Hospital on Wednesday afternoon. Expressing displeasure over delay in the construction work, and the false progress mentioned on the papers, he reprimanded the project manager of the Rajkiya Nirman Nigam. Tired of too many ads? go ad free now A private lecture hall and administrative building (G+2) are being constructed in the surgery department of the LLR at a cost of Rs 18.56 crore. The responsibility of the construction has been assigned to the Rajkiya Nirman Nigam. In the records submitted by project manager RK Gupta, the progress of the work was shown as seven percent but when the district magistrate arrived at the site, he noticed that no construction work was done on the ground floor. Expressing dissatisfaction, the district magistrate stated that the first instalment of Rs 2.51 crore was released almost five months ago but no construction has been done on the ground floor. During the inspection, the DM also reviewed the status of the renovation work in the surgery block. This project, costing Rs 3.79 crore was supposed to be completed by May 31, but it still remains unfinished. The DM instructed that the work must be completed by September 30 at all cost. He also reviewed the progress of the approved works in the orthopaedic block and the maternity ward and directed the officers to complete the works promptly. . TNN
Business Wire
30-05-2025
- Business
- Business Wire
TruTechnologies Secures Significant Growth Investment From LLR Partners
BUSINESS WIRE)-- LLR Partners today announced a strategic growth investment in TruTechnologies ™, a leading provider of real-time clinical trial oversight. LLR's growth capital and value creation resources will be dedicated to helping TruTechnologies' expansion as it transforms how pharmaceutical companies, together with clinical research organizations and research sites, oversee, monitor and manage biological samples and study workflows throughout the clinical trial lifecycle. TruTechnologies aims to enhance workflow efficiency for research sites while enabling real-time visibility and interventions for pharmaceutical companies and clinical research organizations. Its flagship solution, TruLab ®, is a first-of-its-kind mobile-enabled offering for protocol-driven clinical trial oversight, biological sample management and tracking and risk-based monitoring. 'TruTechnologies was founded to solve the ongoing pain point in clinical research of managing biological samples with accuracy, efficiency and compliance,' said Scott Ogle, Co-Founder and CEO of TruTechnologies. 'LLR understands our mission, our customers and our industry. We are excited to partner with LLR as we scale to deliver more value to pharmaceutical companies, clinical research organizations and research sites around the world.' Building on TruLab, TruTechnologies has launched two complementary solutions: TruDose ™, which provides dosing compliance and deviation monitoring, and TruScreen ™, which enables real-time visibility to trial participant screening visits and associated outcomes. "After 25 years in drug development, I've seen firsthand how lack of visibility into study conduct significantly impacts clinical trial outcomes," said Rick Graham, PhD, Co-Founder and Chairman of TruTechnologies. 'That's why I'm so proud of what we've built - a solution that finally brings transparency, accountability and oversight to one of the most overlooked aspects of clinical trial execution." LLR's investment in TruTechnologies builds on its history of partnering with companies driving efficiency and innovation across life sciences and healthcare. 'TruTechnologies has pioneered a differentiated solution in a critical but historically underserved area of clinical trials,' said Zack Sigal, Partner at LLR Partners. William Sadock, Vice President at LLR Partners, added, 'The market TruTechnologies serves is driven by the increasing complexity of clinical trials and demand for more precise, real-time oversight and interventions across the research ecosystem. We are excited to partner with TruTechnologies as they continue to support more clinical teams with real-time insights.' BofA Securities, Inc. served as the exclusive financial advisor to TruTechnologies in this transaction. Wachtell, Lipton, Rosen & Katz served as legal advisor to TruTechnologies. DLA Piper served as legal advisor to LLR Partners. About TruTechnologies Founded in 2018, TruTechnologies is the leading provider of real-time clinical trial oversight, focused on enabling timely, high-quality data and mitigating risks in drug development. The company partners with six top 20 pharmaceutical companies and numerous biotechnology firms to accelerate patient screening and enrollment, drive protocol adherence, and correct deviations. Learn more at and follow on LinkedIn. About LLR Partners LLR Partners is a lower middle market private equity firm investing in technology and healthcare businesses. We collaborate with our portfolio companies to define high-impact growth initiatives, turn them into action and help create long-term value. Founded in 1999 and with more than $7 billion raised across seven funds, LLR is a flexible provider of equity capital for growth, recapitalization and buyouts. Learn more at
Yahoo
24-04-2025
- Business
- Yahoo
LLR Partners Closes Seventh Fund at $2.45 Billion
PHILADELPHIA, April 24, 2025--(BUSINESS WIRE)--LLR Partners, a lower middle market private equity firm, announces the final closing of LLR Equity Partners VII, L.P. (together with its affiliated investment funds, "LLR 7") at $2.45 billion. Included in LLR 7's capital is meaningful participation by LLR's Partners and employees. LLR's prior fund, LLR 6, closed in October 2020 at $1.8 billion, including the General Partner's commitment. "We thank our investors for their partnership and confidence in LLR's investment strategy," said Partner Mitchell Hollin. "We greatly value our Limited Partners, with the entire LLR team striving every day to deliver for them." LLR 7 continues the firm's 25-year history of investing in and partnering with lower middle market growth companies. Like its predecessor funds, LLR 7 will focus on the technology and healthcare sectors. With more than 100 professionals, a dedicated value creation team and a group of experienced executives engaged as Senior Operating Advisors, LLR 7 will invest in majority and minority equity positions, providing capital for growth, recapitalizations and buyouts. "Our thesis-driven investment approach, tech-enabled origination and extensive value creation resources put LLR in prime position to help our companies accelerate growth and become market leaders," said Managing Director, Investor Relations, Jason Jerista. "Our shared objective continues: together, we grow companies every day." Capital commitments for LLR 7 came from a global group of legacy and new investors. LLR 7 began investing in 2024 and has completed investments in five companies: KEEPS, Nonstop Health, Soltis Investment Advisors, Suvoda and TurboTenant. Asante Capital Group acted as placement agent and Latham & Watkins provided legal counsel for LLR 7. About LLR Partners LLR Partners is a lower middle market private equity firm investing in technology and healthcare businesses. We collaborate with our portfolio companies to define high-impact growth initiatives, turn them into action and create long-term value. Founded in 1999 and with more than $7 billion raised across seven funds, LLR is a flexible provider of equity capital for growth, recapitalizations and buyouts. For more information about LLR and insights on accelerating growth, visit View source version on Contacts Media: Emily Oakes, 484-467-8517eoakes@ Investors: Jason Jerista, 215-717-2916jjerista@ Intermediaries: Ann Brophy, 215-883-7116abrophy@ Sign in to access your portfolio
